NKTX

NKTX

Nkarta Inc

Nkarta, Inc. develops allogeneic natural killer cell therapies targeting cancer and autoimmune diseases. Its lead candidate, NKX019, is in Phase 1 trials for various conditions, including lupus nephritis and systemic lupus erythematosus.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $63today

Score Overview

1 Year
Score
Net Growth4.33%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score4.0
Net Growth-13.93%
Net Trend80%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-13.93%
Net Trend80%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency

See the full market ranking →

Nkarta Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 385.00 to $ 0.00 and net income went from -$ 91M to -$ 104M. Revenue increased in 0 of those 5 years; net income in 4.

Nkarta Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.39
1 Year2025-08-12
$ 1.9621.94%
5 Years2021-08-12
$ 37.91-93.70%
All Time2020-07-10
$ 47.90-95.01%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 104M$ 276M
2024$ 0.00-$ 108M$ 267M
2023$ 0.00-$ 117M$ 248M
2022$ 0.00-$ 119M$ 352M
2021$ 0.00-$ 83M$ 238M
IPO2020$ 385.00-$ 91M$ 314M

Explore beyond NKTX

You're looking at Nkarta Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies